Login to My NLA Account

NLA Clinical Recommendations Page 2

The risk of atherosclerotic cardiovascular disease increases with advancing age. Elevated LDL-cholesterol and non-HDL-cholesterol levels remain predictive of incident atherosclerotic cardiovascular events among individuals older than 75 years. Risk prediction among older individuals is less certain because most current risk calculators lack specificity in those older than 75 years and do not adjust for co-morbidities, functional status, frailty, and cognition which significantly impact prognosis in this age group.

Extreme hypertriglyceridemia, defined as triglyceride (TG) levels ≥1000 mg/dL, is almost always indicative of chylomicronemia. The current diagnostic approach categorizes individuals with chylomicronemia into familial chylomicronemia syndrome (FCS; prevalence 1–10 per million), caused by the biallelic combination of pathogenic variants that impair the lipolytic action of lipoprotein lipase (LPL), or multifactorial chylomicronemia syndrome (MCS, 1 in 500). A pragmatic framework should emphasize the severity of the phenotype and the risk of complications.

The following is a National Lipid Association (NLA) Expert Clinical Consensus on the role of apolipoprotein (apo)B in adult patient care. This document is meant to clarify the role of apoB testing for clinicians who manage cardiovascular risk and lipid disorders, as well as health systems, payers, and medical associations. The 2021 NLA Scientific Statement, Lipid Measurements in the Management of section.